Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › TRIUMPH-4 / TRIUMPH-1-OA

TRIUMPH-4 / TRIUMPH-1-OA

Retatrutide · Knee osteoarthritis + obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Retatrutide
Population
Knee osteoarthritis + obesity
Official title
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Sponsor
Eli Lilly and Company
Phase
Phase 3
Registry status
completed · 2023-08 → 2025-11
Participants
1019
Duration
68 weeks
Registry
NCT05929066, NCT05931367

Outcomes in the indication

TRIUMPH-4 / TRIUMPH-1-OA Retatrutide · Knee osteoarthritis + obesity · 68 weeks · n = 1019 verified

WOMAC pain −1.83 (9 mg) and −1.61 (12 mg) points vs placebo on a 0–10 scale at 68 weeks in TRIUMPH-4; −1.35, −1.61 and −1.77 (4/9/12 mg) at 80 weeks in TRIUMPH-1-OA (hybrid-treatment estimand). Weight −15.4 and −19.2 percentage points vs placebo in TRIUMPH-4 (treatment-regimen estimand).

MeasureDrugControlDifference (95 % CI)Status
WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 9 mg
week 68
−4.0−2.1−1.8 (−2.4 to −1.3) pointsverified
WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 9 mg
week 68
−3.6−1.8−1.8 (−2.4 to −1.3) pointsverified
WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 12 mg
week 68
−3.7−2.1−1.6 (−2.2 to −1.1) pointsverified
WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 12 mg
week 68
−3.6−1.8−1.8 (−2.3 to −1.2) pointsverified
WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 4 mg
week 80
−3.2−1.9−1.4 (−1.9 to −0.8) pointsverified
WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 4 mg
week 80
−3.2−1.5−1.7 (−2.2 to −1.1) pointsverified
WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 9 mg
week 80
−3.5−1.9−1.6 (−2.2 to −1.0) pointsverified
WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 9 mg
week 80
−3.4−1.5−1.9 (−2.5 to −1.3) pointsverified
WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 12 mg
week 80
−3.6−1.9−1.8 (−2.3 to −1.2) pointsverified
WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 12 mg
week 80
−3.5−1.5−1.9 (−2.5 to −1.4) pointsverified
Verbatim quotes (10)
  • WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
    was -3.96 with 9-mg, -3.74 with 12-mg retatrutide, and -2.12 with placebo (estimated treatment difference [ETD] vs. placebo [95% CI]: 9-mg: -1.83 [-2.37,-1.30];
  • WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
    Physical Function score (0.22) (0.22) Treatment comparison -1.83 (-2.40, - -1.77 (-2.34, - __
  • WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
    12-mg: -1.61 [-2.16,-1.07], all p<0.001; Table 2, Fig. 1)
  • WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
    -3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53
  • WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
    baseline to week 80 was -3.22 (4-mg) [key secondary endpoint], -3.48 (9-mg), and -3.64 (12- mg) and -1.87 (placebo) (ETD vs. placebo [95% CI]: 4-mg: -1.35 [-1.92,-0.78]; 9-mg: -1.61 [- 2.20,-1.02]; 12-mg: -1.77 [-2.34,-1.20]; all p<0.001; Table 2, Fig. 1)
  • WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
    -3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53
  • WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
    baseline to week 80 was -3.22 (4-mg) [key secondary endpoint], -3.48 (9-mg), and -3.64 (12- mg) and -1.87 (placebo) (ETD vs. placebo [95% CI]: 4-mg: -1.35 [-1.92,-0.78]; 9-mg: -1.61 [- 2.20,-1.02]; 12-mg: -1.77 [-2.34,-1.20]; all p<0.001; Table 2, Fig. 1)
  • WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
    -3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53
  • WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
    baseline to week 80 was -3.22 (4-mg) [key secondary endpoint], -3.48 (9-mg), and -3.64 (12- mg) and -1.87 (placebo) (ETD vs. placebo [95% CI]: 4-mg: -1.35 [-1.92,-0.78]; 9-mg: -1.61 [- 2.20,-1.02]; 12-mg: -1.77 [-2.34,-1.20]; all p<0.001; Table 2, Fig. 1)
  • WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
    -3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53

Related registry entries

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
TRIUMPH-4 / TRIUMPH-1-OA
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
CV outcomesPhase 3completed2023-08 → 2025-11445Completed; results not yet publicNCT05931367
TRIUMPH-1
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
ObesityPhase 3completed2023-07 → 2026-042335Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT05929066

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: TRIUMPH-4 / TRIUMPH-1-OA. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-4-triumph-1-oa/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.